Sep 14, 2023 4:05 pm EDT Mineralys Therapeutics Expands its Board of Directors with Appointments of Glenn Sblendorio and Daphne Karydas
Sep 11, 2023 4:05 pm EDT Mineralys Therapeutics to Participate in the Cantor Fitzgerald Global Healthcare Conference on Thursday, September 28, 2023
Sep 10, 2023 7:47 am EDT Mineralys Therapeutics Announces JAMA Publication of Full Target-HTN Phase 2 Trial Results for Lorundrostat in Uncontrolled and Treatment-Resistant Hypertension
Sep 10, 2023 7:45 am EDT Mineralys Therapeutics Presents Target-HTN Phase 2 Trial Results in Late-Breaking Science Session at 2023 AHA Hypertension Scientific Sessions
Sep 05, 2023 4:05 pm EDT Mineralys Therapeutics Selected for Oral Poster Presentation of Target-HTN Phase 2 Trial Results at 2023 AHA Hypertension Scientific Sessions
Aug 29, 2023 4:05 pm EDT Mineralys Therapeutics to Participate in the Wells Fargo Securities Healthcare Conference on Thursday, September 7, 2023
Aug 07, 2023 4:05 pm EDT Mineralys Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Jul 31, 2023 4:05 pm EDT Mineralys Therapeutics to Announce Second Quarter 2023 Financial Results and Host Conference Call on Monday, August 7, 2023
Jul 17, 2023 4:01 pm EDT Mineralys Therapeutics Announces Expansion of Planned Phase 2 Trial of Lorundrostat Alone and in Combination with SGLT2 Inhibitor to Treat Patients with Chronic Kidney Disease (CKD)
May 31, 2023 8:00 am EDT Mineralys Therapeutics to Participate in the Jefferies Healthcare Conference